Evgen Pharma Plc Harnessing the clinical potential of sulforaphane

Hardman & Co ReportEvgen Pharma Plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. Evgen’s proprietary technology, Sulforadex, creates new and stable variants of sulforaphane, enabling it to be used as a therapeutic for the first time. Its lead candidate, SFX-01, has entered Phase II clinical trials for both subarachnoid haemorrhage (SAH) and ER+ metastatic breast cancer with an expected read out of results in 1H 2018.

 

► Strategy: Evgen is focused on the clinical development of synthetic and stable variants derived from sulforaphane using its proprietary technology, Sulforadex. Lead candidate SFX-01 is entering Phase II trials for both SAH and breast cancer, both strategic entry portals for other uses in neurology and oncology.

► Sulforaphane: An established natural product known to modulate signalling pathways involved in cellular protection (oxidative stress response) and inflammation. However, use of sulforaphane as a therapeutic has been held back by its instability, a problem resolved using the Sulforadex technology.

► SFX-01: First of a potential series of stable synthetic variants of sulforaphane. Patient recruitment has commenced, and is about to commence, for Phase II clinical trials in subarachnoid haemorrhage and ER+ metastatic breast cancer respectively. Headline results are expected during 1H 2018.

► Risks: As with all drug development companies, there is a risk that products will fail in clinical trials. However, sulforaphane has been through a number of encouraging clinical trials despite its stability and dosing limitations. Therefore, the Evgen Pharma Plc risk profile is arguably reduced.

► Investment summary: SFX-01 would be entering multi-billion dollar global markets which are currently unsatisfied. There is also potential use in other indications. Evgen intends to out-license its drugs to the pharmaceutical majors for global commercialisation. The enterprise value afforded Evgen by the market does not reflect properly the development stage and lower than usual risk profile of SFX-01.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Evgen Pharma Plc

    21 Health Benefits of Broccoli

    Are you looking for a vegetable to spice up your diet in a healthy way? If yes, then broccoli, also called Brassica oleracea italica, is the vegetable you want. The dark green crucifer is not only

    Evgen Pharma Plc

    12 things that are actually tied to breast cancer

    According to the Centres for Disease Control and Prevention (CDC), breast cancer is the most common cancer in women. In the US, one in eight women will develop breast cancer during her lifetime. Those statistics sound

    Evgen Pharma Plc

    10 subtle signs of breast cancer

    A diagnosis of breast cancer can be terrifying. According to the CDC, Breast cancer is the most common cancer in American women of any race or ethnicity. Though the statistics might be scary, catching breast cancer

    Evgen Pharma Plc

    Evgen Pharma plc Investor Presentation in Manchester

    Evgen Pharma plc (LON: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that Steve Franklin, the Company’s CEO, will be presenting tomorrow evening at a ShareSoc Growth

    Evgen Pharma Plc

    ‘I never knew men could get breast cancer’

    Moses Musonga never thought men could get breast cancer until he was diagnosed with the disease in 2013. The 67-year-old Kenyan told the BBC that he was profoundly shock when doctors told him in 2013 that

    Evgen Pharma Plc

    Male Breast cancer:What are the signs and how to check?

    Breast cancer is more commonly associated with women more than with men, affecting approximately one in eight women in their lifetimes. However, men can still be diagnosed with breast cancer, albeit in far rarer circumstances. While